Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $89.2M | $101M | $106M | $117M | $129M | $154M | $162M | $193M | $220M | $250M |
| Revenue growth | — | 13.1% | 4.7% | 11.0% | 10.4% | 19.4% | 4.7% | 19.7% | 13.6% | 13.5% |
| Gross profit | $62.9M | $70.7M | $73.9M | $79.9M | $84.6M | $101M | $105M | $127M | $151M | $179M |
| Gross margin | 70.6% | 70.1% | 70.0% | 68.1% | 65.4% | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
| Operating income | $16.3M | $21.1M | $28.2M | $21.2M | $28.8M | $36.4M | $26.8M | $36.7M | $52.3M | $67.9M |
| Operating margin | 18.3% | 20.9% | 26.7% | 18.1% | 22.3% | 23.6% | 16.6% | 19.0% | 23.8% | 27.2% |
| Net income | $10.6M | $17.2M | $22.9M | $17.9M | $21.2M | $26.9M | $20.6M | $30.1M | $44.0M | $57.7M |
| Net margin | 11.9% | 17.0% | 21.7% | 15.3% | 16.4% | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
| EPS (diluted) | $0.55 | $0.86 | $1.13 | $0.88 | $1.04 | $1.25 | $0.93 | $1.34 | $1.93 | $2.52 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $16.9M | $22.9M | $19.5M | $14.2M | $34.8M | $35.1M | $25.4M | $36.8M | $44.1M | $81.3M |
| Capital expenditures | $2.84M | $6.42M | $3.05M | $3.76M | $2.98M | $4.88M | $3.23M | $7.26M | $6.96M | $6.78M |
| Free cash flow | $14.1M | $16.5M | $16.5M | $10.4M | $31.8M | $30.2M | $22.1M | $29.5M | $37.2M | $74.5M |
| Share buybacks | $311K | $778K | $741K | $683K | $570K | $802K | $642K | $853K | $1.72M | $1.82M |
| Dividends paid | $3.32M | $4.18M | $5.45M | $6.74M | $7.70M | $9.34M | $11.0M | $12.4M | $14.4M | $18.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.3M | $19.1M | $26.3M | $11.8M | $26.8M | $13.9M | $19.1M | $24.3M | $25.6M | $28.2M |
| Total assets | $102M | $126M | $153M | $188M | $253M | $293M | $310M | $347M | $552M | $616M |
| Total liabilities | $14.4M | $16.6M | $22.9M | $40.2M | $80.2M | $38.7M | $42.3M | $48.9M | $215M | $222M |
| Shareholders' equity | $87.5M | $110M | $130M | $148M | $173M | $254M | $268M | $298M | $337M | $394M |
| Retained earnings | $15.3M | $28.3M | $45.8M | $57.0M | $70.6M | $88.1M | $97.8M | $115M | $145M | $185M |
| Shares (wtd avg diluted) | 19.2M | 20.0M | 20.2M | 20.3M | 20.5M | 21.5M | 22.2M | 22.4M | 22.8M | 22.9M |
Every figure is extracted from LEMAITRE VASCULAR INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.